Onkologie. 2014:8(6):259-263

Gastrointestinal stromal tumors, morphological and immunohistochemical study. Forceps versus endoscopic

Dušan Žiak1,2, Jana Dvořáčková1,2,3, Pavel Hurník1,2,3, Vladimír Židlík2, Jarmila Šustíková2, Jarmila Šimová2, Magdalena Uvírová2, Radoslava Tomanová1, Martin Kliment5, Ondřej Urban5, Vincent Zoundjiekpon5, Oldřich Motyka4, Petr Dítě6
1 Ústav patologie Fakultní nemocnice Ostrava
2 CGB laboratoř a.s., Vzdělávací a výzkumný institut AGEL, o.p.s. – pobočka Ostrava-Vítkovice
3 Lékařská fakulta Ostravské univerzity, Ostrava
4 Oddělení anorganické analýzy, Centrum nanotechnologií, Vysoká škola báňská – Technická univerzita, Ostrava
Centrum péče o zažívací trakt Vítkovická nemocnice, Vzdělávací a výzkumný institut AGEL, o.p.s. –
5 pobočka Ostrava-Vítkovice
6 Interní klinika Fakultní nemocnice Ostrava

ultrasound-guided fine-needle aspiration biopsy

Gastrointestinal stromal tumors (GIST) belong to the most common mesenchymal tumors of digestive tract deriving from Cajal interstitial

cells. A panel of immunohistochemical antibodies CD117, desmin, S100 and DOG1 is used to confirm the morphological diagnosis. When

evaluating the biological characteristics we used a Miettinen classification for GIST which divides tumors into three groups according to

a risk of aggressive behaviour. This classification observes three parameters – tumor localisation, its size and mitotic index. Mitotic index is

defined as a number of mitoses in the tumor tissue on the overall area of 5 mm2. We performed a comparison of sampling methods – biopsy

forceps, resection versus endoscopic ultrasound-guided fine-needle aspiration cytology (EUS FNA) from the point of view of a pathologist,

focusing on the assessment of all necessary morphological and prognostic parameters of neoplasia. The study conclusions and experience

show that when diagnosing GISTs, results of cytological examination of a sample using EUS FNA are comparable to those using forceps endoscopic

biopsy. The main limitation of EUS FNA method is that in 75 % of cases it is impossible to state the mitotic index due to insufficient

amount of tumor tissue. This tissue deficit may be replaced with an examination of a nuclear protein associated with cell proliferation Ki 67

which appears to be an independent prognostic parameter of disease progression.

Keywords: gastrointestinal stromal tumor, fine needle aspiration cytology – EUS FNA, biopsy forceps, mitotic index, Ki-67, prognostic

Published: December 15, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žiak D, Dvořáčková J, Hurník P, Židlík V, Šustíková J, Šimová J, et al.. Gastrointestinal stromal tumors, morphological and immunohistochemical study. Forceps versus endoscopic. Onkologie. 2014;8(6):259-263.
Download citation

References

  1. Rosai J. Ackerman's surgical pathology. 8. Vydání. St. Louis, MO: mosby, 1996. Sv. 1.
  2. WHO. Mezinárodní klasifikace nemocí pro onkologii: česká verze. 3. vydání. Praha: Ústav zdravotnických informací a statistiky, 2004.
  3. Koh JS, Trent J, CHen L, et al. Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histopatology 2004; 9(2): 565-574.
  4. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30(10): 1213-1220. Go to original source... Go to PubMed...
  5. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438(1) Go to original source... Go to PubMed...
  6. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005; 41: 2868-2872. Go to original source... Go to PubMed...
  7. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003; 54: 3-2.
  8. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005; 29(1): 52-68. Go to original source... Go to PubMed...
  9. Miettinen M, Lasota J. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13(3): 205-220. Go to original source... Go to PubMed...
  10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83. Go to original source... Go to PubMed...
  11. Daum O, Šedivcová M. Doporučený postup pro histologické vyšetření gastrointestinálních stromálních tumorů. CZ1401164954-01/2014.
  12. Rossi G, Valli R, Bertolini F, Marchioni A, Cavazza A, Mucciarini C, Migaldi M, Federico M, Trentini GP, Sgambato A. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology. 2005; 46(5): 522-531. Go to original source... Go to PubMed...
  13. Doyle LA, Hornick JL. Gastrointestinal stromal tumors: From KIT to succinate dehydrogenase. Histopathology. 2014; 64(1): 53-67. Go to original source... Go to PubMed...
  14. Belev B, Brčić I, Prejac J, Golubić ZA, Vrbanec D, Božikov J, Alerić I, Boban M, Razumović JJ. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. J Gastroenterol. 2013; 19(4): 523-7. Go to original source... Go to PubMed...
  15. Wen-Yi Zhao, Jia Xu, Ming Wang, Zi-Zhen Zhang, Lin Tu, Chao-Jie Wang, Tian-Long Lin, Yan-Yin Shen, Qiang Liu, Hui Cao. Prognostic value of Ki67 index in gastrointestinal stromal tumors, Int J Clin Exp Pathol. 2014; 7(5): 2298-2304.
  16. Jiang J, Jin MS, Suo J, Wang YP, He L, Cao XY. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors., J Gastroenterol. 2012; 18(20): 2569-2575. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.